- Home
- PINS vs UTHR Comparison
PINS vs UTHR Comparison
Compare PINS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINS
- UTHR
- Stock Information
- Founded
- PINS 2008
- UTHR 1996
- Country
- PINS United States
- UTHR United States
- Employees
- PINS N/A
- UTHR N/A
- Industry
- PINS Computer Software: Programming Data Processing
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- PINS Technology
- UTHR Health Care
- Exchange
- PINS Nasdaq
- UTHR Nasdaq
- Market Cap
- PINS 22.2B
- UTHR 20.7B
- IPO Year
- PINS 2019
- UTHR 1999
- Fundamental
- Price
- PINS $27.31
- UTHR $457.50
- Analyst Decision
- PINS Buy
- UTHR Buy
- Analyst Count
- PINS 31
- UTHR 12
- Target Price
- PINS $39.33
- UTHR $495.08
- AVG Volume (30 Days)
- PINS 16.3M
- UTHR 586.0K
- Earning Date
- PINS 11-04-2025
- UTHR 10-29-2025
- Dividend Yield
- PINS N/A
- UTHR N/A
- EPS Growth
- PINS 824.42
- UTHR 16.08
- EPS
- PINS 2.88
- UTHR 26.38
- Revenue
- PINS $4,056,550,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- PINS $18.65
- UTHR $13.68
- Revenue Next Year
- PINS $14.96
- UTHR $5.63
- P/E Ratio
- PINS $9.38
- UTHR $17.02
- Revenue Growth
- PINS 16.79
- UTHR 13.50
- 52 Week Low
- PINS $23.68
- UTHR $266.98
- 52 Week High
- PINS $40.90
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- PINS 33.34
- UTHR 62.14
- Support Level
- PINS $25.87
- UTHR $444.04
- Resistance Level
- PINS $27.58
- UTHR $456.41
- Average True Range (ATR)
- PINS 1.00
- UTHR 14.56
- MACD
- PINS -0.65
- UTHR 0.83
- Stochastic Oscillator
- PINS 18.92
- UTHR 66.98
About PINS Pinterest Inc.
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.